Claimed effect · Orforglipron

Does Orforglipron help with blood glucose?

A
Grade A — established in humansPhase 3 RCT (n=559) + programme · effect size: large
Short answerEstablished in humans. Phase 3 RCT (n=559) + programme point the same way: a large effect. ACHIEVE-1, 40 weeks in type 2 diabetes managed by diet and exercise alone: HbA1c fell 1.24–1.48 points versus 0.41 on placebo, bringing the average to 6.5–6.7%.

What the studies show

ACHIEVE-1, 40 weeks in type 2 diabetes managed by diet and exercise alone: HbA1c fell 1.24–1.48 points versus 0.41 on placebo, bringing the average to 6.5–6.7%.

“At week 40, the estimated mean change from baseline in the glycated hemoglobin level was -1.24 percentage points with the 3-mg dose, -1.47 percentage points with the 12-mg dose, -1.48 percentage points with the 36-mg dose, and -0.41 percentage points with placebo.”

Verbatim, from the abstractRosenstock J, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes (ACHIEVE-1). N Engl J Med, 2025;393:1065–1076

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1

In context

Orforglipron (Foundayo) is a once-daily tablet that activates the GLP-1 receptor. It is not a peptide — it is a small molecule, which is why it survives digestion and needs no injection, refrigeration or food restriction. Its phase 3 programme is published: about 11% average weight loss over 72 weeks in obesity, and HbA1c reductions of roughly 1.5 points in early type 2 diabetes. The FDA approved it for weight management on 1 April 2026. The effect is smaller than injected tirzepatide or semaglutide; the delivery is far easier.

Orforglipron is approved (rx) — united states. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Orforglipron proven to help with blood glucose?
Yes, as far as human trials can show it: Phase 3 RCT (n=559) + programme. LYO grades this outcome A.
What studies are behind the grade?
ACHIEVE-1, 40 weeks in type 2 diabetes managed by diet and exercise alone: HbA1c fell 1.24–1.48 points versus 0.41 on placebo, bringing the average to 6.5–6.7%.
Is Orforglipron approved for this?
Orforglipron is an approved medicine (Approved (Rx) — United States); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Orforglipron

Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →